abacavir (ziagen) Report issue

Small molecule Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Abacavir is a nucleoside reverse transcriptase inhibitor used for treatment of HIV infection (either alone or in combination with other antiviral drugs). It was shown that abacavir exerts its antiviral activity through its active metabolite, carbovir triphosphate. Carbovir triphosphate is a guanine analogue and a potent and selective inhibitor of viral reverse transcriptases. Upon administration, abacavir is first converted to abacavir monophosphate by ADK, then the monophosphate is deaminated to carbovir monophosphate, which is then anabolized by cellular kinases to carbovir diphosphate and then finally to carbovir triphosphate. Abacavir causes hypersensitivity reaction in patients with HLA-B*57:01 allele.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.4492 - $9.1703

Australia

$2.9597 - $51.7280
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( abacavir (ziagen), lamivudine (epivir) )
|
( abacavir (ziagen), dolutegravir (tivicay), lamivudine (epivir) )
|
( abacavir (ziagen), lamivudine (epivir), zidovudine (retrovir) - other name: abacavir sulfate; lamivudine; zidovudine )

Alternative names

1592u89 | (1s,4r)-4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol | {(1s-cis)-4-[2-amino-6-(cyclopropylamino)-9h-purin-9-yl]cyclopent-2-en-1-yl}methanol | abacavir | abacavir (as sulfate) / lamivudine / zidovudine | abacavir - lamivudine | abacavir / lamivudine | abacavir-lamivudine combination | abacavir, lamivudine drug combination | abacavir succinate | abacavir sulfate | abacavir sulfate / dolutegravir sodium / lamivudine | abacavir sulfate-lamivudine combination | abc | epzicom | kivexa | lamivudine / zidovudine / abacavir sulfate | ziagen

Organizations (179)

Research & Development (170)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Acidosis, Lactic (Phase 2/Phase 3)

Acquired Immunodeficiency Syndrome (Phase 4)

Aicardi Syndrome (Phase 2)

AIDS Dementia Complex (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)

Antiretroviral Therapy, Highly Active (Phase 4)

Arthralgia (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Atrophy (Phase 4)

Cardiovascular Diseases (Phase 4)

Cognition Disorders (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Gout (Phase 2)

Healthy Volunteers (Phase 1)

Hepatitis C (Phase 1)

Herpesvirus 8, Human (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

Hypercholesterolemia (Phase 4)

Lipodystrophy (Phase 4)

Organ Transplantation (Phase 4)

Patient Compliance (Phase 4)

Proteinuria (Phase 4)

Psoriasis (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Sarcoma, Kaposi (Phase 4)

Tuberculosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 199
  • # of Trial Organizations: 170

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue